Mylan Announces Comtan® Settlement Agreement

                 Mylan Announces Comtan® Settlement Agreement

PR Newswire

PITTSBURGH, Dec. 20, 2012

PITTSBURGH, Dec. 20, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today
announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a
settlement agreement with Orion Corporation that will resolve patent
litigation related to Entacapone Tablets, 200 mg. Entacapone Tablets are the
generic version of Orion's Comtan^®, indicated as an adjunct to
levodopa/carbidopa therapy to treat patients with idiopathic Parkinson's
Disease who experience the signs and symptoms of end-of-dose "wearing-off".

Under the terms of the settlement agreement, Mylan may launch a generic
version of Comtan, 200 mg, on April 1, 2013, at the earliest. Pursuant to the
agreement, pending litigation will be dismissed. All other terms and
conditions of the settlement are confidential, and the agreement itself is
subject to review by the U.S. Department of Justice and the Federal Trade
Commission.

Entacapone Tablets, 200 mg, had U.S. sales of approximately $104.9 million for
the 12 months ending Sept. 30, 2012, according to IMS Health.

This press release includes statements that constitute "forward-looking
statements," including with regard to the settlement of the litigation and
sales of the product. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Because
such statements inherently involve risks and uncertainties, actual future
results may differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause or contribute to such
differences include, but are not limited to: any legal or regulatory
challenges to the settlement; strategies by competitors or other third parties
to delay or prevent product introductions; risks inherent in legal and
regulatory processes; and the other risks detailed in the company's periodic
filings with the Securities and Exchange Commission. The company undertakes no
obligation to update these statements for revisions or changes after the date
of this release.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service a habit, do what's right, not what's easy and impact
the future through passionate global leadership. We offer a growing portfolio
of more than 1,100 generic pharmaceuticals and several brand medications. In
addition, we offer a wide range of antiretroviral therapies, upon which
approximately one-third of HIV/AIDS patients in developing countries depend.
We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 150 countries and
territories. Our workforce of more than 18,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside. mylan.com

SOURCE Mylan Inc.

Website: http://www.mylan.com
Contact: Nina Devlin (Media), +1-724-514-1968, Kris King (Investors),
+1-724-514-1813
 
Press spacebar to pause and continue. Press esc to stop.